ABP-745 Dose A
Sponsors
Atom Therapeutics Co., Ltd
Conditions
ASCVDASCVD ManagementAcute Gout FlareAcute Gouty ArthritisAtherosclerosis Cardiovascular DiseaseGout FlareGout Flares
Phase 2
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
RecruitingNCT07145229
Start: 2025-08-26End: 2026-06-30Target: 380Updated: 2025-12-08
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
RecruitingNCT07303777
Start: 2026-04-23End: 2028-04-01Target: 200Updated: 2026-04-28